Evidence map›Paper›PMID 38646532›Full record

ArticleFrontiers in immunology2024

Case report: Novel compound heterozygous

Elena Urbaneja, Nuria Bonet, Manuel Solis-Moruno, Anna Mensa-Vilaro, Iñaki Ortiz de Landazuri, Marc Tormo, Rocio Lara, Susana Plaza, Virginia Fabregat, Jordi Yagüe and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Elena Urbaneja *Department of Immunology and Pediatric Rheumatology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Nuria Bonet *Genomics Core Facility, Departament de Medicina i Ciències de la Vida (MELIS), Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
Manuel Solis-Moruno *Genomics Core Facility, Departament de Medicina i Ciències de la Vida (MELIS), Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
Anna Mensa-VilaroDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Iñaki Ortiz de LandazuriDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Marc TormoGenomics Core Facility, Departament de Medicina i Ciències de la Vida (MELIS), Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
Rocio LaraDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Susana PlazaDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Virginia FabregatDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Jordi YagüeDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Ferran CasalsDepartament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Juan I ArosteguiDepartment of Immunology, Hospital Clínic, Barcelona, Spain.
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESBarcelona Biomedical Research Park · ESHospital Clínico Universitario de Valladolid · ESInstitut de Biomedicina de la Universitat de BarcelonaPompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Undiagnosed monogenic diseases represent a challenging group of human conditions highly suspicious to have a genetic origin, but without conclusive evidences about it. We identified two brothers born prematurely from a non-consanguineous healthy couple, with a neonatal-onset, chronic disease characterized by severe skin and bone inflammatory manifestations and a fatal outcome in infancy. We conducted DNA and mRNA analyses in the patients' healthy relatives to identify the genetic cause of the patients' disease. DNA analyses were performed by both Sanger and next-generation sequencing, which identified two novel heterozygous

Indexed as

HeterozygoteInterleukin 1 Receptor Antagonist ProteinMutationPedigreeFatal OutcomeFemaleHereditary Autoinflammatory DiseasesHumansInfant, NewbornMalePhenotypeIL1RN protein, humanInterleukin 1 Receptor Antagonist Proteinautoinflammatory diseases (AID)case reportinterleukin-1interleukin-1 receptor antagonist (IL-1 ra)whole-genome sequencing (WGS)

Identifiers

PMID38646532
PMCPMC11026629
OpenAlexW4393986750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.